RT Journal Article
SR Electronic
T1 Clinical and epidemiological characteristics of Madariaga and Venezuelan equine encephalitis virus infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.02.24302220
DO 10.1101/2024.02.02.24302220
A1 Rivera, Luis Felipe
A1 Lezcano-Coba, Carlos
A1 Galué, Josefrancisco
A1 Rodriguez, Xacdiel
A1 Juarez, Yelissa
A1 de Souza, William M.
A1 Capitan-Barrios, Zeuz
A1 Valderrama, Anayansi
A1 Abrego, Leyda
A1 Cedeño, Hector
A1 Jackman, Carmela
A1 Waggoner, Jesse J.
A1 Aguilar, Patricia V.
A1 Guzman, Hilda
A1 Weaver, Scott C.
A1 Tesh, Robert B.
A1 López-Vèrges, Sandra
A1 Donnelly, Christl A.
A1 Estofolete, Cassia F.
A1 Nogueira, Mauricio L.
A1 Faria, Nuno R.
A1 Vasilakis, Nikos
A1 Vittor, Amy Y.
A1 Smith, Darci R.
A1 Carrera, Jean-Paul
YR 2024
UL http://medrxiv.org/content/early/2024/02/03/2024.02.02.24302220.abstract
AB Madariaga virus (MADV) and Venezuelan equine encephalitis virus (VEEV) are emerging arboviruses affecting rural and remote areas of Latin America. However, there are limited clinical and epidemiological reports available, and outbreaks are occurring at an increasing frequency. We addressed this gap by analyzing all the available clinical and epidemiological data of MADV and VEEV infections recorded since 1961 in Panama. A total of 168 of human alphavirus encephalitis cases were detected in Panama from 1961 to 2023. Here we describe the clinical signs and symptoms and epidemiological characteristics of these cases, and also explored signs and symptoms as potential predictors of encephalitic alphavirus infection when compared to those of other arbovirus infections occurring in the region. Our results highlight the challenges clinical diagnosis of alphavirus disease in endemic regions with overlapping circulation of multiple arboviruses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by the Armed Forces Health Surveillance Division (AFHSD), Global Emerging Infections Surveillance (GEIS) Branch, ProMIS ID P0052_23_NM awarded to DRS. JPC is funded by the Clarendon Scholarship from the University of Oxford (grant number SFF1920_CB2_MPLS_1293647). This work was supported by SENACYT, through the grant FID-2021-96 grant to JPC; the National Institute of Allergy and Infectious Diseases, the National Institutes of Health (grant K08AI110528 to JJW), and the Centers for Research in Emerging Infectious Diseases (CREID) Coordinating Research on Emerging Arboviral Threats Encompassing the NEOtropics (CREATE-NEO) 1U01AI151807 grant awarded to NV and KAH by the National Institutes of Health (NIH) and by the World Reference Center for Emerging Viruses and Arboviruses (NIH R24 AI120942 to SCW). CAD was supported by the NIHR HPRU in Emerging and Zoonotic Infections, a partnership between PHE, the University of Oxford, the University of Liverpool, and the Liverpool School of Tropical Medicine (grant no. NIHR200907). WMS is supported by the Global Virus Network fellowship and the NIH (AI12094) Global Virus Network fellowship, Burroughs Wellcome fund (#1022448) and Wellcome Trust-Digital Technology Development award (Climate Sensitive Infectious Disease Modelling (226075/Z/22Z). MLN is a CNPq Research Fellow, and it is supported by a FAPESP grant # 22/03645-1). BPD Is a CNPq Research Fellow. NRF acknowledges support from Bill and Melinda Gates Foundation (INV034540), and Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0). AYV acknowledges Research Command, NCRADA-NMRC-20-10993.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of human data and samples from outbreaks was approved by the Panamanian Ministry of Health (protocol number 2077, protocol: 365/CBI/ICGES/2023, approved on November 30, 2023), and the Gorgas Memorial Institute (GMI) IRB (protocol: 335/CBI/ICGES/21, protocol: 073/CBI/ICGES/21 and protocol 138/CBI/ICGES/22, approved on March 19, 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.